When was Juvenescence founded?

Juvenescence was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Juvenescence located?

Juvenescence is headquartered in Dublin, Ireland. It is registered at 41 King Sreet, Liverpool, United Kingdom, L19 8EE.

Is Juvenescence a funded company?

Juvenescence is a funded company, having raised a total of $290M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 06, 2017.

How much is Juvenescence worth?

The latest valuation of Juvenescence is $***** as of May 09, 2022.

When was the latest funding round of Juvenescence?

Juvenescence's latest funding was a $***** Series B round on May 07, 2025, with participation from 1 investor.

What is the annual revenue of Juvenescence?

Annual revenue of Juvenescence is less than $1M as on Dec 31, 2024

Where does Juvenescence rank among its competitors?

Juvenescence ranks 152nd amongst 3683 active competitors, of which 1267 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of Juvenescence?

Juvenescence's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Senti Bio secured the most recent funding round in May, 2026.

Juvenescence - 2026 Company Profile, Team, Funding, Competitors & Financials

Juvenescence is a series B company based in Dublin (Ireland), founded in 2017 by Jim Mellon and Greg Bailey. It operates as a Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health. Juvenescence has raised $290M in funding from investors like Foresite Capital, Fastforward Innovations and IDO Investments, with a current valuation of $*****. The company has 3683 active competitors, including 1267 funded and 849 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health. The company offers keto-diet-based exogenous ketone which helps in metabolic switches and provides anti-aging properties and protection from other age-related diseases like neurodegenerative diseases, immunosenescence & cell damage. The product is C6 Ketone Di-Ester which can raise the levels of ketones in the blood to generate ketosis.

Website: juvlabs.com
Social
Registered Address: 41 King Sreet, Liverpool, United Kingdom, L19 8EE

Key Metrics

Founded Year

2017

Location

Dublin, Ireland

Stage

Series B

Total Funding

$290M in 7 rounds

Latest Funding Round

Series B, May 07, 2025, $*****

Post Money Valuation

$***** as on May 09, 2022

Investors

Foresite Capital & 10 more

Ranked

152^nd among 3683 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2024

Investment & Acquisitions

Ro5 & 8 more

Similar Companies

Jazz Pharmaceuticals & 3539 more

View Juvenescence's full profile

Juvenescence is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
JUVENESCENCE (EUROPE) LIMITED CIN: 675938 , Ireland, Active	Aug 18, 2020	$0 - $1M (As on Dec 31, 2024)	-	-
Juvenescence Limited CIN: 10081257 , United Kingdom, Active	Mar 22, 2016	-	-
JUVENESCENCE US CORP. CIN: 83-1728509 , United States, Active	Aug 14, 2018	-	21 (As on Dec 31, 2021)	-

Juvenescence has raised a total funding of $290M over 7 rounds. Its first funding round was on Dec 06, 2017. Its latest funding round was a Series B round on May 07, 2025 for $*****. 1 investor participated in its latest round. Juvenescence has 9 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Juvenescence:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 07, 2025	4935169	Series B	8985506	1832214	2513292	6314730
Sep 30, 2019	1039910	Series B	6966520	9056126	1675222	6464517
Aug 19, 2019	1449769	Series B	5038823	6519971	Grok Ventures & 1 more	9117201

Access funding benchmarks and valuations. Sign up today!

View details of Juvenescence's funding rounds and investors

The founders of Juvenescence are Jim Mellon and Greg Bailey. Greg Bailey is the CEO of Juvenescence.

Here are the details of Juvenescence's key team members:

Jim Mellon: Co-Founder of Juvenescence and founder of 4 other companies, including Agronomics, Burnbrae Group and Dev Academy. They are also an angel investor in 11 startups.
Contact Info: 3 email addresses
Greg Bailey: Co-Founder & CEO of Juvenescence and founder of 2 other companies, Dev Academy and Juvenescence.
Contact Info: 1 email address

View details of Juvenescence's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Juvenescence include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Juvenescence, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
152nd	Juvenescence 2017, Dublin (Ireland), Series B	Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health	$290M	Foresite Capital, Apeiron Investment Group ... & 9 others	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Juvenescence's competitors? Click here to see the top ones

Juvenescence has made 8 investments in companies including LyGenesis and Morphoceuticals. Juvenescence has also acquired 1 companies including Ro5.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Apr 2025	Acquisition	Ro5	2018	London (United Kingdom)
Oct 05, 2023	Investments	LyGenesis	2017	Pittsburgh (United States)
Jan 23, 2023	Investments	Morphoceuticals	2020	Marblehead (United States)